| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
Human Endogenous Metabolite
Pristanic acid does not have a specific receptor target. It is a fatty acid that is metabolized in peroxisomes via β-oxidation. It is a ligand for peroxisome proliferator-activated receptor alpha (PPARα), a nuclear receptor that regulates lipid metabolism. Its accumulation in the body is a hallmark of peroxisomal disorders, such as Refsum disease and Zellweger syndrome. |
|---|---|
| ln Vitro |
Endogenous metabolites are those that the Kyoto Encyclopedia of Genes and Genomes has identified as products or substrates of the approximately 1900 metabolic enzymes that are encoded in human genome. Numerous of these metabolites have been shown to have harmful effects, as evidenced by the body of literature [1].
In vitro, Pristanic acid is used as a tool to study fatty acid metabolism and peroxisomal function. It can be used as a substrate to measure the activity of enzymes involved in branched-chain fatty acid oxidation. It is also used as a standard in lipidomics and analytical chemistry. It may be used to activate PPARα in cell-based assays to study its effects on gene expression. |
| ln Vivo |
In vivo, Pristanic acid is an endogenous metabolite present in blood plasma. It is derived from the metabolism of phytanic acid. Its accumulation in the body is a biomarker for peroxisomal disorders. It is not used as a therapeutic agent. Its primary relevance is in the study of lipid metabolism and peroxisomal function.
|
| Enzyme Assay |
For non-cell-based assays, Pristanic acid is used as an analytical standard for the identification and quantification of fatty acids in biological samples using techniques like GC-MS and LC-MS. It is also used as a substrate in enzyme assays to measure the activity of enzymes involved in branched-chain fatty acid oxidation.
|
| Cell Assay |
For in vitro cellular assays, Pristanic acid can be used to study PPARα activation. Cells expressing PPARα are treated with the compound, and the expression of PPARα target genes is measured by qPCR. It can also be used to study the effects of fatty acids on cellular metabolism and signaling. However, its primary use is as a research tool in lipid metabolism.
|
| Animal Protocol |
For in vivo animal studies, Pristanic acid can be administered to rodents to study its effects on lipid metabolism and peroxisomal function. In models of peroxisomal disorders, the compound's accumulation and metabolism are assessed. However, its primary use is as a research tool and a biomarker.
|
| ADME/Pharmacokinetics |
Pristanic acid has a molecular weight of 298.51 and a molecular formula of C19H38O2. It is a branched-chain fatty acid. The compound is soluble in organic solvents. It should be stored at -20°C for long-term stability. It is for research use only and is not intended for human consumption.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Pristanic acid has not been extensively reported. At physiological concentrations, it is not considered toxic. However, its accumulation in peroxisomal disorders is pathogenic. The compound is for research use only and is not intended for human consumption. Standard safety precautions should be observed when handling the compound.
|
| References |
|
| Additional Infomation |
Pristanic is a branched-chain, long-chain saturated fatty acid composed of pentadecanoic acid with methyl substituents at positions 2, 6, 10, and 14. It is a human metabolite. Pristanic is a branched-chain saturated fatty acid, a long-chain fatty acid, and a methyl-branched fatty acid. It is the conjugate acid of Pristanic esters. There are reports and relevant data regarding the presence of Pristanic in humans.
Pristanic acid (CAS 1189-37-3) is a branched-chain fatty acid. It is a terpenoid acid present in the blood plasma of healthy individuals. It plays a critical role in lipid metabolism and is an important compound for studying peroxisomal disorders. It is available for research purposes only. |
| Molecular Formula |
C19H38O2
|
|---|---|
| Molecular Weight |
298.50
|
| Exact Mass |
298.287
|
| CAS # |
1189-37-3
|
| PubChem CID |
123929
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
0.882g/cm3
|
| Boiling Point |
408ºC at 760 mmHg
|
| Flash Point |
14ºC
|
| Vapour Pressure |
8.48E-08mmHg at 25°C
|
| Index of Refraction |
1.453
|
| LogP |
6.146
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
21
|
| Complexity |
260
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)CCCC(C)CCCC(C)CCCC(C)C(=O)O
|
| InChi Key |
PAHGJZDQXIOYTH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H38O2/c1-15(2)9-6-10-16(3)11-7-12-17(4)13-8-14-18(5)19(20)21/h15-18H,6-14H2,1-5H3,(H,20,21)
|
| Chemical Name |
2,6,10,14-tetramethylpentadecanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (167.50 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3501 mL | 16.7504 mL | 33.5008 mL | |
| 5 mM | 0.6700 mL | 3.3501 mL | 6.7002 mL | |
| 10 mM | 0.3350 mL | 1.6750 mL | 3.3501 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
